Clinical
In the past 20 years, immunological methods have been used to detect tumor cells in peripheral blood [2] [3] [4] , bone marrow , and lymph nodes [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] . Several studies using these methods for the identification of bone marrow micrometastases have shown an increased risk for recurrent disease in patients with localized tumor plus micrometastatic disease [7, 9, 13-16, 29, 30, 32, 33] . Immunological and other methods of micrometastasis detection, however, have not been incorporated into staging protocols. Reverse transcriptase-PCR (RT-PCR) is the most recent method to be used in micrometastasis detection.' In RT-PCR, the enzyme reverse transcriptase converts mRNA into cDNA, which is then amplified by PCR. RT-PCR has thus far been used for detection of micrometastases of carcinoma of the prostate [56- 8 1] , breast [82] [83] [84] [85] [86] [87] [88] [89] [90] , liver [91] [92] [93] , colorectum [94, 95] , stomach [83, 87] , esophagus [87] , pancreas [83] , and lung [96] , as well as melanoma [97] [98] [99] [100] [101] [102] [103] , neuroblastoma [1 04-107] , and hematopoietic malignancies [108, 109] . Critical long-term follow-up data, however, are not yet available, and hence the role of RT-PCR for micrometastases detection in cancer staging is not established. In this review we summarize data from the literature regarding micrometastasis detection by immunological and molecular techniques.
Materials and Methods
To review the literature, we used a Medline search of all English-language articles from January 1976 to December 1995. Search terms used were RT-PCR, adenocarcinoma, prostatic neoplasms, immunology, flow cytometry, and tumor markers. Fisher's exact two-tailed test was used for statistical analysis of the cumulative data presented later ( Table 3 ). The P-values reported in Tables 1 and 2 were the values reported in the individual studies. For studies without reported P-values, we evaluated the results by the Fisher's exact two-tailed test.
For this discussion, we use the term micrometastasis to mean a metastasis from a nonhematopoietic malignancy that is not detected with conventional clinicopathological methods of staging. This has different meanings based on the location involved (blood, bone marrow, or lymph node). Conventional staging methods do not test for circulating tumor cells; therefore, micrometastasis detected in venous blood refers to any detectable circulating tumor cells. Bone marrow micrometastasis is Table 1 . DetectIon by Immunohistochemical
(IHC), immunofluorescent (IF), and RT-PCR methods of bone marrow (BM) and hematogenous (H) micrometastasis
at the time of surgery compared with subsequent development of distant metastasis.
No. of patients (and %)
No. of Carclnoma/
Study patients method
Mansi et al. [9) 350 Breasta/lHCBM Diel et a). [14) 211 Breast8/IHC-BM Harbeck et al. [15] 100 Breast/IHC.BM Cote et al. [7] 49 Breasta/lFBM
Osborne et a). (6] 348 Breast/lF-BM Dearnaley et al. [13) of the expected number of cells [23] [24] [25] . However, these methods have been found to be relatively precise, and the number of micrometastases has been found to be a significant predictor for recurrent disease [6, 7, 11, 12, 38] . In a pilot study by Cote et al. [7] , multivariate analysis of the clinicopathological features of 49 breast cancer patients showed that the ratio of cancer cells to nucleated cells C)
in bone marrow was the only significant variable for prediction of early recurrence. Seven of 13 patients with >10 cancer cells per 4 X 106 NC had a recurrence, whereas none of the 5 patients with fewer than this number had recurrent disease during the 30-month median follow-up period. In a larger multivariate analysis of 348 breast cancer patients [6] , a finding of >14 cells per 4 X 10 NC was the most important predictor of tumor recurrence.
Others found that >20 cancer cells per a mean of 76.5 X i0 NC (range = 6X iO to 210 X i0 NC) was a predictor of recurrence [11, 12] . In a study of 197 neuroblastoma patients [38] , immunocytological detection of bone marrow micrometastasis provided greater sensitivity than conventional cytological detection, and a low number of bone marrow micrometastases (<6 neuroblastoma cells per l0 NC) was associated with progression-free survival in patients older than 1 year (n = 37) with stage II or III neoplasms (P = 0.001). Additionally, in patients younger than 1 year at diagnosis (n = 13), progression-free survival was less in those with >20 tumor cells per i05 bone marrow cells (P = 0.03).
Despite evidence of prognostic value, bone marrow micrometastasis detection has not gained widespread use in cancer staging protocols.
Standardization of techniques (e.g., cell concentration methods, antibody panels, number of cells counted, aspiration sites) to detect micrometastases has been recommended [5] . In a recent review of bone marrow micrometastasis detection in patients with breast cancer [5] , Osborne and Rosen state, At present, most patients with invasive breast cancer are eligible for systemic therapy if the invasive tumor exceeds 1.0 cm. . . . The practicality of demonstrating a beneficial effect of systemic adjuvant chemotherapy in patients with bone marrow micrometastases who are not currently recommended to receive such therapy is questionable. The relapse rate in these patients is about 10% in 10 years.
Thus, it remains unclear whether the application of this information will result in improvements in outcome for all groups of patients. Other difficulties have also contributed to the lack of widespread use of immunological methods, including loss of antigen expression in poorly differentiated tumors, reports of CK [129] 60, 137, 139] . In comparison, PSA mRNA expression has been shown to be androgen-dependent and to be decreased in more poorly differentiated tumors [140] . At a lower limit of detection of 1 cell per 106 NC, there is a 70% chance of a positive RT-PCR result with a 5-mL blood sample and a total of 1000 tumor cells evenly distributed within a patient's circulation [141] . The importance of this level of [82, 84, 86] . Amplification of carcinoembryonic antigen mRNA has been used to detect bone marrow micrometastases in breast, colorectal, pancreatic, and gastric cancer [83] and to detect lymph node micrometastases in breast, colorectal, gastric, and esophageal cancer [87] . Amplification of surfactant proteins A, C, and D has been used to detect lymph node micrometastases in non-small-cell lung cancer [96] . For neuroblastoma patients, RT-PCR was used to amplify neuroendocrine protein gene product 9.5 mRNA in the peripheral blood of eight patients [104] and tyrosine hydroxylase mRNA in the blood and bone marrow [105] [106] [107] . These studies highlight the diversity of RT-PCR applications that are under investigation. [155, 156] , and adhesion molecule expression [157, 158] . In the future, in addition to improved methods of detection, identification of markers associated with more-aggressive tumor behavior will result in more-specific, and potentially more clinically significant, detection of micrometastases.
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Current RT-PCR assays for detecting micrometastatic tumor cells are primarily limited by lack of tumor-specific markers. PSA is one of the most specific tumor markers; however, PSA expression has been demonstrated in breast tumors, breast milk, breast cystic fluid, normal endometrium, and amniotic fluid [141, 159, 160] . Studies have also detected PSA mRNA in the peripheral blood of patients without prostate cancer, which suggests that low amounts of PSA mRNA may be present in the circulation [133, 134] . Smith et al. [133] , using nested RT-PCR and a total of 80 amplification cycles, found positive results in 13 of 13 control patients (7 men, 6 women). Decreasing the total number of cycles to 50 still resulted in positive results in 10 of 13 controls, whereas none of the patients were positive in 40 cycles of nonnested RT-PCR. Henke et al. [134] , also using a total of 80 cycles, obtained positive results in 12 of 31 control patients.
In both of these studies, the RT-PCR product was sequenced to validate PSA mRNA detection. In the studies summarized in Table 3 , the majority of studies utilized a total of 3 5-50 amplification cycles, with one study using 60 [63] and another 70 cycles [68] . The single positive result in a "control" patient in these studies occurred when a total of 50 amplification cycles was used. The patient was a 61-year-old man with renal cell carcinoma, a normal serum PSA, and a normal digital rectal examination, but no prostate biopsy [59] . Performing additional PCR amplification cycles has resulted in "false" positives not only for PSA mRNA amplification but also in a breast cancer study using amplification of CK19 mRNA [90] and in a melanoma study using amplification of tyrosinase mRNA [97] . In nonprostatic cancers, tumor markers are less specific.
Studies attempting to detect circulating tumor cells in patients with hepatocellular carcinoma have found amplified AFP and albumin mRNA in patients with benign liver disease [92, 93] . MUC1 mRNA amplification combined with Southern transfer in breast cancer studies has resulted in false-positive results for lymph node and peripheral blood samples in control patients; the finding was attributed to overamplification of background mRNA [85] . In a melanoma study, false-positive results obtained in two patients by tyrosinase mRNA amplification were attributed to needle contamination by cutaneous melanocytes during venipuncture [101] . The problem was eliminated by obtaining two consecutive blood samples and testing the second sample, which would be less likely to be contaminated.
CK18 mRNA amplification produced false-positive results that appeared to be attributable to amplification of a pseudogene [83] . Early attempts at amplification of keratin 19 mRNA resulted in amplification of a pseudogene;
subsequently, more-specific primers were designed [86, 90, 94] . Other false-positive results were obtained for normal lymph nodes in amplification of mRNAs for heat shock protein 89, estrogen receptor, p52, and epithelial membrane antigen [90] . Positive findings have also been obtained in control lymph nodes by amplification of surfactant protein B mRNA in a study of patients with non-small-cell lung cancer, whereas amplification of surfactant proteins A, C, and D mRNA was negative in control lymph nodes [96] . In comparative studies, however, RT-PCR is more sensitive than immunohistochemical methods for detecting micrometastases in peripheral blood [104] , bone marrow [75, 76] , and lymph nodes [81, 88] .
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Pelkey et al.: Detection of circulating tumor cells and micrometastases defines the detection limit as "the smallest concentration or amount of an analyte that can be reliably shown to be present or measured under defined condition" [163] . One of the difficulties in comparing the detection limits listed in Table 4 
